Knowledge Sourcing Intelligence announces the publication of a new analysis report on the “Extracorporeal membrane oxygenation machine market” - which is forecasted from 2021 to 2028. The prime factors propelling the growth of the...

Knowledge Sourcing Intelligence announces the publication of a new analysis report on the “Extracorporeal membrane oxygenation machine market” - which is forecasted from 2021 to 2028.
The prime factors propelling the growth of the extracorporeal membrane oxygenation machine market are the alarming rates of increases in pulmonary and cardiovascular diseases such as respiratory infections, heart attacks, rheumatic heart diseases, etc.
As per the report, the extracorporeal membrane oxygenation machine market is anticipated to increase significantly during the forecast period.
The extracorporeal membrane oxygenation machine market is experiencing significant growth due to the rising rates of pulmonary and cardiovascular diseases such as heart attacks, asthma, respiratory infections, etc. Cardiovascular diseases are classified as a major source of deaths by the World Health Organization with almost one in every three deaths being caused by cardiovascular diseases. Out of this percentage, almost 85% of all deaths are caused by heart attacks and strokes. Additionally, with the spread of the coronavirus and its effects on the heart and lungs, the rates of cardiovascular and pulmonary diseases have increased. Therefore, the market for extracorporeal membrane oxygenation machines is also expected to be boosted as a result of this.
The extracorporeal membrane oxygenation machine market has been categorized based on product, component, modality outlook, and geography.
By product, the market has been classified into ECMO machines and software. The ECMO machine segment is expected to witness significant growth in the coming years due to its usage in hospitals and clinics for open heart surgeries and transplants, as well as relieving pressure on the lungs. On the other hand, the ECMO software segment is anticipated to experience steady growth owing to its ability to provide a simulation environment for ECMO training, as well as using cloud services to connect doctors with patient data in real-time.
By component, the market has been classified into pumps, oxygenators, cannul, and accessories. The pump segment is anticipated to witness significant growth in the coming years due to the usage of ECMO pumps for pumping blood outside the patient’s body, allowing the heart and lungs to rest. The ECMO oxygenator segment is also expected to grow, as it helps in pumping oxygen into the body and simultaneously removes carbon dioxide from the blood. The ECMO cannul segment is anticipated to experience significant growth in the forecast period too as it is required for the different types of ECMO-base lung support functions. The market for ECMO accessories is also expected to grow to proportionate to the overall ECMO market.
By modality outlook, the market has been classified into veno-venous, veno-arterials, and arterio-venous. The veno-venous segment is expected to witness positive growth in the extracorporeal membrane oxygenation machine market, owing to the rise in the use of veno-venous systems for covid-19 treatment and the increasing amount of respiratory disorders. The veno-arterial segment is anticipated to experience significant growth due to multiple applications of the device, reimbursement policies for these, and the rise in the rates of cardiovascular diseases. The arterio-venous segment of the ECMO machine market is also expected to witness steady growth due to improved medical evaluation facilities, and an effective dynamic range of applications.
Based on geographic region, the market is classified into North America, South America, Europe, the Middle East and Africa, and Asia Pacific. The Asia Pacific region is witnessing significant investments in the healthcare sector. Additionally, this region is also accountable for a large percentage of the world population, which, in turn, results in an increase in the demand for ECMO machines to treat numerous cardiovascular and pulmonary diseases. On the other hand, the North American market is expected to hold a significant share of the ECMO machines market due to the presence of an established healthcare sector with rising demand for modern technological medical devices for treatments. Another reason for the growth of the market in this region relates to the increasing number of related diseases due to unhealthy diets and stressful working conditions.
As a part of the report, the major players operating in the extracorporeal membrane oxygenation machine market that have been covered are Medtronics plc, LivaNova, Terumo Cardiovascular Systems Corporation, Nipro Medical Corporation, Microport Scientific Corporation, Getinge AB, Xenios AG, EUROSETS, ABIOMED.
View a sample of the report or purchase the complete study at https://www.knowledge-sourcing.com/report/extracorporeal-membrane-oxygenation-machine-market
This analytics report segments the extracorporeal membrane oxygenation machine market on the following basis:
- By Product
- ECMO Machine
- Software
- By Component
- Pumps
- Oxygenators
- Cannul
- Accessories
- By Modality Outlook
- Veno-Venous
- Veno-Arterials
- Arterio-Venous
- By Geography
- North America
- USA
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- UK
- Germany
- France
- Spain
- Others
- Middle East and Africa
- Saudi Arabia
- UAE
- Others
- Asia Pacific
- Japan
- China
- India
- South Korea
- Indonesia
- Thailand
- North America
Others
Need specialized data cuts or competitive intelligence?
Our analyst team provides bespoke market sizing, supplier audits, and country-level feasibility reports tailored to your enterprise roadmap.
Speak With an Industry Analyst →Ask an Industry Analyst
Have questions regarding this briefing or market projections? Inquire with our sector lead.
Related Press Releases
View All →
ADC Manufacturing & CDMO Market is expected to reach USD 10.49 billion by 2031
Aug 7, 2026
Lifestyle-Associated Cancer Epidemiology Market is expected to reach USD 13.12 billion by 2031
Aug 5, 2026
Psycho-Oncology Digital Health Market is anticipated to surpass USD 290.01 million in 2031 at a CAGR of 8.5%
Jul 30, 2026
Intratumoral Injection Therapy Market is expected to reach USD 630.39 million by 2031
Jul 24, 2026
Palliative Care in Oncology Market is expected to reach USD 244.1 billion by 2031
Jul 22, 2026More Press Releases
Oncology Drug Resistance Testing Market is projected to reach USD 3.41 billion in 2031 at a CAGR of 6.6 %
The oncology drug resistance testing market is expanding due to rising cancer prevalence, increasing drug resistance, and growing adoption of precision oncology. Advances in NGS-based testing, companion diagnostics, and targeted therapies, alongside FDA approvals and investments in personalized medicine, are accelerating demand for effective resistance monitoring across hospitals and clinical diagnostics worldwide.
TROP-2 Targeted Therapy Market is anticipated to surpass USD 3.29 billion in 2031 at a CAGR of 8.6 %
The TROP-2 Targeted Therapy market is expanding rapidly due to increasing precision oncology adoption, rising cancer prevalence, and growing use of antibody-drug conjugates. North America leads the market, while Asia Pacific shows the fastest growth. Continuous clinical trials, regulatory approvals, and strategic collaborations are accelerating innovation and commercial adoption worldwide.
Second Primary Cancer Prevention Market is expected to reach USD 24.7 billion by 2031
The Second primary cancer prevention refers to strategies aimed at reducing the risk of developing a new, unrelated cancer in individuals with a prior cancer diagnosis. Growing cancer survivorship, advances in treatment, and increasing awareness of long-term health outcomes have heightened the importance of prevention and surveillance programs. Key approaches include routine screening, genetic risk assessment, lifestyle modification, and long-term follow-up care. Government agencies and healthcare organisations increasingly emphasise survivorship care plans and evidence-based screening protocols to detect new malignancies at earlier stages. Continued investments in early detection technologies and personalised risk assessment are expected to support advancements in second primary cancer prevention.